Semaglutide , the active ingredient in Ozempic, Wegovy, and Rybelsus , has transformed the treatment of type 2 diabetes and obesity. But for millions of Americans, brand-name versions remain out of reach due to cost, insurance exclusions, or persistent shortages. That gap fueled an unprecedented boom in compounded semaglutide, often prescribed through telehealth platforms. Now, a sweeping regulatory shift is underway. New FDA rules taking effect in 2026 will dramatically restrict compounding of semaglutide, reshaping access for patients and forcing telehealth prescribers to rethink their care models. This article explains what is changing, why it matters, and what patients and clinicians need to know.
Understanding the Semaglutide Compounding Landscape
Compounding is the practice of preparing customized medications for individual patients when an FDA-approved drug is not appropriate or available. Traditionally, compounding pharmacies mix drugs based on a specific prescription , for example, a patient allergic to a dye in a commercial tablet. But in recent years, large-scale compounding of semaglutide has operated on a different scale. Facilities registered as outsourcing facilities under Section 503B of the Federal Food, Drug, and Cosmetic Act have produced semaglutide in bulk, supplying telehealth companies that prescribe it to thousands of patients at a fraction of the brand-name price.
This practice exploded after semaglutide was placed on the FDA's drug shortage list in 2022. When a drug is in shortage, compounding pharmacies may legally prepare copies of it , even at scale , as long as they meet certain conditions. For semaglutide, the shortage designation opened the floodgates. Telehealth startups, weight-loss clinics, and med-spas began offering compounded semaglutide for $200 to $400 per month, compared with $900 to $1,300 for brand-name Ozempic or Wegovy without insurance. Patients flocked to these services, often after being denied coverage by their insurers.
However, the FDA has long warned that compounded semaglutide is not the same as the approved product. The agency has received reports of dosing errors, adverse events, and quality problems linked to compounded versions. Some compounding pharmacies have used semaglutide salts , such as semaglutide sodium or semaglutide acetate , which are not the same as the base semaglutide used in FDA-approved drugs. These salt forms have not been tested for safety or efficacy in humans, and the FDA has explicitly stated they are not permitted for compounding.
What the 2026 FDA Rules Change
The 2026 rules do not ban compounding of semaglutide outright. Instead, they tighten the conditions under which compounding is allowed, effectively ending the large-scale, shortage-driven market that has dominated the past few years. The key changes fall into three areas:
- Shortage status removal: The FDA removed semaglutide from its drug shortage list in late 2024, after Novo Nordisk demonstrated it could meet demand. Once a drug is no longer in shortage, 503B outsourcing facilities may no longer compound it in bulk. The FDA has given compounding pharmacies a transition period , originally set to end in 2025, but extended into 2026 after legal challenges and supply chain concerns. Under the final guidance, most bulk compounding of semaglutide must cease by early 2026.
- Restrictions on salt forms: The FDA has clarified that only the base form of semaglutide may be used in compounding. Semaglutide salts are not considered the same active ingredient and cannot be legally compounded. This rule eliminates a significant portion of the gray-market supply.
- Enhanced oversight of telehealth prescribing: While the FDA does not directly regulate the practice of medicine, it has worked with state pharmacy boards and the Drug Enforcement Administration to crack down on telehealth platforms that prescribe semaglutide without adequate patient evaluation. New rules require a valid patient-practitioner relationship, documented medical necessity, and proper informed consent before compounded semaglutide can be prescribed.
These changes are not a surprise. The FDA signaled its intent years ago, and the agency has issued multiple warning letters to compounding pharmacies and telehealth companies. But the 2026 deadline marks the end of the transition period and the beginning of strict enforcement.
Impact on Patients: Access, Cost, and Safety
For patients currently using compounded semaglutide, the 2026 rules create a hard deadline. After the transition period ends, they will no longer be able to obtain compounded semaglutide from 503B outsourcing facilities , the source of most telehealth-prescribed product. They will face three choices: switch to a brand-name medication, find a traditional compounding pharmacy that can legally prepare a customized version for a specific medical need, or stop treatment.
The cost implications are significant. Brand-name semaglutide remains expensive for uninsured or underinsured patients. Ozempic and Wegovy list for over $900 per month, and while manufacturer savings cards and patient assistance programs exist, they do not cover everyone. Many patients who turned to compounded semaglutide did so precisely because they could not afford the brand. For them, the 2026 rules may mean losing access to a medication that was working.
Safety is the other side of the coin. The FDA's crackdown is driven by legitimate concerns about quality and consistency. Compounded semaglutide is not subject to the same rigorous testing as FDA-approved drugs. Some compounding pharmacies have been found to produce subpotent or superpotent batches, and there have been reports of contamination. The salt forms, in particular, have no established safety profile. By restricting compounding, the FDA aims to protect patients from unknown risks , but that protection comes at the cost of affordability and convenience.
Patients who have been using compounded semaglutide should not panic, but they should plan. The transition period gives them time to explore alternatives, talk to their prescriber, and check insurance coverage. Some may qualify for manufacturer patient assistance programs. Others may find that their insurance now covers semaglutide for weight loss , a shift that has accelerated as employers recognize the long-term cost savings of treating obesity. Still others may be candidates for alternative GLP-1 medications, such as tirzepatide (Mounjaro, Zepbound), which may have different coverage or cost profiles.
Impact on Telehealth Prescribers
Telehealth platforms built their semaglutide businesses on the compounding loophole. For many, the 2026 rules represent an existential threat. Companies that relied on prescribing compounded semaglutide at scale will need to pivot quickly , or shut down. The new rules require telehealth prescribers to:
- Verify the source of any compounded medication: Prescribers must ensure that any compounded semaglutide they prescribe comes from a pharmacy that is legally operating under the new rules. This means no more bulk orders from 503B facilities after the transition period.
- Document medical necessity: Compounded semaglutide can only be prescribed when a patient has a specific medical need that cannot be met by the FDA-approved product , for example, an allergy to an inactive ingredient or a need for a different dosage form. Telehealth prescribers must document this necessity in the patient's record.
- Conduct thorough evaluations: The days of asynchronous questionnaires and five-minute video calls are over. Prescribers must establish a legitimate patient-practitioner relationship, which typically requires a real-time interaction, a review of medical history, and appropriate follow-up. Many state medical boards have tightened their telehealth rules in parallel with the FDA's actions.
- Provide informed consent: Patients must be told that compounded semaglutide is not FDA-approved, that its safety and efficacy have not been established, and that they are choosing it over an approved alternative. This consent must be documented.
Some telehealth companies are already adapting. Several have shifted their focus to prescribing brand-name semaglutide when covered by insurance, or to other GLP-1 medications that remain in shortage and can still be compounded legally. Others are partnering with traditional compounding pharmacies that can meet the stricter requirements for individualized prescriptions. But the economics are challenging. Traditional compounding is more expensive than bulk outsourcing, and the patient volume is much lower. The telehealth semaglutide boom may simply be over.
What About Traditional Compounding Pharmacies?
Not all compounding is affected equally. Traditional compounding pharmacies , those that prepare medications for individual patients based on a specific prescription , can still compound semaglutide under certain conditions. The 2026 rules do not ban this practice; they simply require that the compounding be done for a legitimate medical need and not as a way to circumvent the FDA approval process.
However, the FDA has made clear that it will scrutinize traditional compounding of semaglutide closely. If a pharmacy is compounding semaglutide in large quantities, using salt forms, or advertising it as a cheaper alternative to Ozempic or Wegovy, the agency will consider that a violation. Traditional compounding pharmacies must also comply with state pharmacy board rules, which vary widely. Some states have already moved to restrict semaglutide compounding even before the federal rules take effect.
For patients with a genuine medical need , such as an allergy to an inactive ingredient in the brand-name product , traditional compounding may still be an option. But they will need a prescriber who is willing to document that need and a pharmacy that is willing to take on the regulatory risk. Many pharmacies are choosing not to compound semaglutide at all, given the scrutiny.
Legal Challenges and Uncertainty
The 2026 rules have not gone unchallenged. The Outsourcing Facilities Association, a trade group representing 503B compounding pharmacies, sued the FDA over the removal of semaglutide from the shortage list. The lawsuit argued that the FDA's decision was arbitrary and that semaglutide remains in short supply in many areas. A federal court initially sided with the trade group, temporarily blocking the FDA's enforcement. But the FDA appealed, and the case is still working its way through the courts. The 2026 deadline reflects the FDA's expectation that it will prevail, but the legal landscape could shift.
In addition, several states have introduced legislation to protect patient access to compounded semaglutide. These bills would allow state-licensed pharmacies to continue compounding semaglutide even if the FDA restricts it, under the theory that states have primary authority over the practice of pharmacy. Whether such laws would survive a federal preemption challenge is unclear. For now, patients and prescribers should assume that the federal rules will take effect as scheduled in 2026.
What Patients Should Do Now
If you are currently taking compounded semaglutide, do not wait until the last minute. Here are practical steps to take before the 2026 deadline:
- Talk to your prescriber: Ask whether your current telehealth provider will continue to offer semaglutide after the rules change. If not, ask for a referral to a clinician who can prescribe an alternative.
- Check your insurance coverage: Many insurers have expanded coverage for GLP-1 medications, especially for type 2 diabetes. Even if you were denied before, your plan may have changed. Call your insurer or check your formulary online.
- Explore patient assistance programs: Novo Nordisk offers a patient assistance program for uninsured patients who meet income criteria. Other manufacturers have similar programs. Your prescriber's office can help you apply.
- Consider alternative medications: Tirzepatide (Mounjaro, Zepbound) is another GLP-1 receptor agonist that may be more affordable or more likely to be covered by insurance. Liraglutide (Saxenda, Victoza) is an older option with generic versions available in some countries, though not yet in the U.S.
- Do not buy from unregulated sources: The crackdown will likely drive some patients to online sellers of unapproved semaglutide. These products are dangerous , they may be counterfeit, contaminated, or mislabeled. Never buy semaglutide from a website that does not require a prescription.
The Bigger Picture: A Shifting GLP-1 Market
The 2026 semaglutide compounding rules are part of a larger transformation in the GLP-1 market. As more drugs in this class gain approval and as manufacturing capacity expands, the shortage-driven compounding era will fade. Novo Nordisk and Eli Lilly are investing billions in new production facilities. Oral semaglutide and other next-generation drugs are on the horizon. Over time, prices may fall, and insurance coverage may broaden. But that transition will be painful for patients who have come to rely on compounded semaglutide as an affordable option.
For telehealth prescribers, the message is clear: the era of easy semaglutide prescriptions is ending. Those who want to stay in the GLP-1 space will need to